Research programme: BAG3 protein modulators - Biouniversa

Drug Profile

Research programme: BAG3 protein modulators - Biouniversa

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator BIOUNIVERSA
  • Class
  • Mechanism of Action Apoptosis regulatory protein modulators; Signal transducing adaptor protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders

Most Recent Events

  • 01 Aug 2016 Preclinical trials in Cardiovascular disorders in Italy (unspecified route)
  • 01 Aug 2016 Preclinical trials in Cancer in Italy (unspecified route)
  • 01 Aug 2016 Research programme: BAG3 protein modulators - Biouniversa is available for licensing as of 01 Aug 2016. http://www.biouniversa.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top